http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3426310-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7ef8e49cf6c9998b2ec47149f9866482 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B2017-00274 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B2018-00547 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B10-0045 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57434 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57438 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57488 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-40 |
| filingDate | 2017-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_079698ae31503bf783d465e1317ee24b |
| publicationDate | 2019-01-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-3426310-A1 |
| titleOfInvention | Prostatic liquid biopsy for the detection of prostate cancer and benign prostatic hyperplasia |
| abstract | Disclosed are methods to induce dislodgement of target prostatic cells from the prostate organ, collecting said cells, and subsequently examining the cell population. Such methods comprise the administration of an agent that facilitates the dislodgement of the target cells from within the prostate, which then migrate into the urethra. Exemplary agents include 5 alpha-reductase inhibitors. The cells induced to pass into the urethra are then collected non-invasively, such as through urine or semen samples. Such collection is further strategically calculated relative the administration of the agent so as to maximize the sample collection of the target cells of interest. The exfoliated prostatic epithelial cells are subsequently utilized for purposes such as detecting prostate cancer, predicting/measuring prostate tumor susceptibility to drug regimes, active surveillance of patients whose prostate biopsy results are negative, but continue to exhibit symptoms consistent with prostate cancer, and identifying false positive results associated with biomarker assays. |
| priorityDate | 2016-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 77.